Self-pay still important in China's health system
This article was originally published in Scrip
An analysis of patient records from one major hospital in a provincial capital city in China indicates just how important the self-pay market in the country still is, despite the steady national expansion of rural and other medical insurance schemes.
You may also be interested in...
Takeda is confident about the promise of its first-in-class molecule for higher-risk myelodysplastic syndromes after positive Phase II data.
While Xtandi has positive new survival data in prostate cancer, other rivals in the competitive market are reporting the same at ASCO.
Join Scrip and the Pink Sheet’s Asia content team for a wide-ranging look at the ongoing multiple impacts of the pandemic on the pharma industry.